Hims & Hers Health (NYSE:HIMS) Sees Large Volume Increase – What’s Next?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually-high trading volume on Thursday . Approximately 12,205,356 shares changed hands during trading, an increase of 37% from the previous session’s volume of 8,904,333 shares.The stock last traded at $23.51 and had previously closed at $27.60.

Analysts Set New Price Targets

HIMS has been the topic of several recent research reports. TD Cowen increased their target price on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 8th. Truist Financial increased their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Bank of America increased their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 21st. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.21.

Hims & Hers Health Stock Performance

The company’s 50-day moving average price is $19.51 and its 200 day moving average price is $18.77. The stock has a market capitalization of $4.70 billion, a PE ratio of 53.43 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period last year, the company posted ($0.04) EPS. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. Analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the transaction, the director now directly owns 23,917 shares of the company’s stock, valued at $362,342.55. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the transaction, the director now directly owns 23,917 shares of the company’s stock, valued at $362,342.55. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total transaction of $331,050.00. Following the sale, the insider now owns 196,941 shares of the company’s stock, valued at approximately $4,346,487.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 854,547 shares of company stock valued at $15,987,230 in the last three months. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC increased its stake in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new stake in Hims & Hers Health during the 2nd quarter valued at about $111,000. CWM LLC increased its stake in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank grew its stake in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after acquiring an additional 2,354 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.